These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 27439682)

  • 1. Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.
    Kurozumi S; Yamaguchi Y; Kurosumi M; Ohira M; Matsumoto H; Horiguchi J
    J Hum Genet; 2017 Jan; 62(1):15-24. PubMed ID: 27439682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.
    Bottai G; Diao L; Baggerly KA; Paladini L; Győrffy B; Raschioni C; Pusztai L; Calin GA; Santarpia L
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
    Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.
    Sakurai M; Masuda M; Miki Y; Hirakawa H; Suzuki T; Sasano H
    Int J Biol Markers; 2015 May; 30(2):e190-9. PubMed ID: 25907662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
    Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
    Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
    Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
    Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs in breast cancer pathogenesis.
    Götte M
    Minerva Ginecol; 2010 Dec; 62(6):559-71. PubMed ID: 21079577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Relevance of microRNA Expressions in Breast Cancer Validated Using the Cancer Genome Atlas (TCGA).
    Kim SY; Kawaguchi T; Yan L; Young J; Qi Q; Takabe K
    Ann Surg Oncol; 2017 Oct; 24(10):2943-2949. PubMed ID: 28766230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
    Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling.
    Dai X; Chen A; Bai Z
    Sci Rep; 2014 Oct; 4():6566. PubMed ID: 25338681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of triple negative breast cancer (TNBC): current options and future perspectives.
    De Laurentiis M; Cianniello D; Caputo R; Stanzione B; Arpino G; Cinieri S; Lorusso V; De Placido S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S80-6. PubMed ID: 21129616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inferring coregulation of transcription factors and microRNAs in breast cancer.
    Wu JH; Sun YJ; Hsieh PH; Shieh GS
    Gene; 2013 Apr; 518(1):139-44. PubMed ID: 23246694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.
    Andorfer CA; Necela BM; Thompson EA; Perez EA
    Trends Mol Med; 2011 Jun; 17(6):313-9. PubMed ID: 21376668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction of an initial microRNA regulation network in breast invasive carcinoma by bioinformatics analysis.
    Yin Y; Shen C; Xie P; Cheng Z; Zhu Q
    Breast; 2016 Apr; 26():1-10. PubMed ID: 27017236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
    Li D; Xia H; Li ZY; Hua L; Li L
    Biomed Res Int; 2015; 2015():746970. PubMed ID: 25961039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.
    Santarosa M; Maestro R
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):131-42. PubMed ID: 22101651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.